Vaccination and Immunization

Ocugen, Inc. has submitted a request to the US Food and Drug Administration for emergency use authorization (EUA) for their COVID-19 vaccine candidate for use in children aged 2-18 years.

Effective vaccines are one of the greatest public health achievements. Dr. Tina Q. Tan shares how the November issue is dedicated to vaccines, from the history to tackling vaccine hesitancy.

Contemporary Pediatrics sat down with editor-in-chief Dr. Tina Q. Tan to discuss the approval of the COVID-19 vaccine for children aged 5 to 11 years and conversations with parents.

The US Food and Drug Administration (FDA) has amended the emergency use authorization of the Pfizer/BioNTech vaccine to include children aged 5 to 11 years.

The US Food and Drug Administration (FDA) committee voted on whether the emergency use authorization should be extended to children aged 5 to 11 years.

The US Food and Drug Administration (FDA) is meeting to discuss amending the emergency use authorization of the Pfizer/BioNTech vaccine for children aged 5 to 11 years.

Seqirus’s FLUCELVAX® cell-based quadrivalent influenza vaccine has been approved to expand the age indication to children as young as 6 months of age by the US Food and Drug Administration.

Initial results from the trial indicate it was well-tolerated and promoted a good immune response.

Anthony S. Fauci, MD, Director of the National Institute of Allergy and Infectious Disease, reveals when he believes a COVID-19 vaccine for children aged less than 12 years will be available.

The American Academy of Pediatrics (AAP) has issued its recommendations for the upcoming influenza season, including guidance on administering the vaccine to patients with COVID-19.

Although the vaccine rollout has snagged, the effort has already saved thousands.

Merck has released promising topline results from their study of VAXNEUVANCE™, a 15-valent pneumococcal conjugate vaccine, in infants.

Faced with the fourth highest vaccine exemption rate, Michigan began requiring an education session before a parent could get a nonmedical exemption. Did it lead to an improvement?

Today’s vaccine approval opens up the ability to administer it off-label to children aged younger than 11 years. A statement from the American Academy of Pediatrics (AAP) discourages doing so.

How medical practices can create effective vaccination programs for the months ahead

For children who have either experienced a delay in pertussis vaccination or who haven’t received the recommended number of doses, what is their risk of pertussis? A new study provides answers.

Patient portals can be a powerful communication tool for both clinician and family, but can they also be used to improve uptake of the annual influenza vaccine?

Rotavirus can lead to gastrointestinal concerns that can be hazardous to children when rehydration isn’t readily available, which means that a safe, effective vaccine could be life-saving. A meta-analysis examines the safety and efficacy of available immunizations.

Educating families to alleviate fear in pediatric populations regarding the flu vaccine will improve the vaccination rate and protect high-risk children. Due to the negative effects of the flu in children with diabetes, it is vital that at-risk youth be vaccinated.

Contemporary Pediatrics speaks with Dr. Jeffrey Gerber about when we will see COVID-19 vaccines for children aged less than 12 years.

There are many reasons why a caregiver may refuse to have his or her child receive the human papillomavirus (HPV) vaccine, including safety concerns. A research letter examines whether those concerns have increased.

The last meeting of the COVID-19 vaccine congress from the International Society for Vaccines (ISV) provided information on the hypersensitivity events tied to mRNA vaccines as well as the most recent information on the Janssen and Novavax vaccines.

The company has publicized data from the TeenCOVE study of the vaccine along with plans to seek authorization in the coming weeks.

The American Academy of Pediatrics (AAP) issued a statement that urges parents get all children and teenagers aged 12 and older vaccinated with Pfizer/BioNTech vaccine, which recently had its authorization expanded.

The US Food and Drug Administration expanded the emergency use authorization of the 2-dose vaccine to include children aged 12 to 15 years.

The International Society for Vaccines (ISV) presented its fifth update on COVID-19 vaccines around the world. This update focused on vaccines produced in China.

Tackling vaccine hesitancy for the coronavirus disease 2019 (COVID-19) is going to be an important component of achieving the herd immunity needed to end the pandemic.

Pfizer/BioNTech has released data on their coronavirus disease 2019 (COVID-19) vaccine that indicates that its highly effective in children aged 12 to 15 years.

Moderna announces beginning of coronavirus disease 2019 (COVID-19) vaccine trial that include children aged 6 months to >12 years.

A safe coronavirus 2019 disease (COVID-19) vaccine that can be administered to most of the pediatric population is a necessity for ending the pandemic, but trials for younger children have not occurred. The president of the American Academy of Pediatrics (AAP) wrote to key COVID-19 officials about the need to change this.